Vaccine 2004, 22:1570–1575.PubMedCrossRef
26. Capiau C, Desmons P: Method for isolating and purifying Bordetella pertussis antigenic factors. In In Book Method for isolating and purifying Bordetella pertussis antigenic factors (Editor ed.^eds.), vol. 5391715. City: SmithKline Beecham Biologicals; click here 1995. 27. Chong P, Jackson G, Cwyk W, Klein M: Simultaneous determination of Bordetella pertussis toxin and filamentous haemagglutinin concentrations by hydroxyapatite high-performance liquid chromatography. J Chromatogr 1990, 512:227–236.PubMedCrossRef 28. Hewlett EL, Sauer KT, Myers GA, Cowell JL, Guerrant RL: Induction of a novel morphological response in Chinese hamster ovary cells by pertussis toxin. Infect Immun 1983, 40:1198–1203.PubMed 29. Sauer B: Functional expression of the cre-lox site-specific recombination system in the yeast Saccharomyces cerevisiae . Mol Cell Biol 1987, 7:2087–2096.PubMed 30. Charles I, Fairweather N, Pickard
D, Beesley J, Anderson R, Dougan G, Roberts M: Expression Alisertib of the Bordetella pertussis P.69 pertactin adhesin in Escherichia coli: fate of the carboxy-terminal domain. Microbiology 1994,140(Pt 12):3301–3308.PubMedCrossRef 31. Frohlich BT, De Bernardez Clark ER, Siber GR, Swartz RW: Improved pertussis toxin production by Bordetella pertussis through adjusting the growth medium’s ionic composition. J Biotechnol 1995, 39:205–219.PubMedCrossRef 32. Stainer DW, Scholte MJ: A simple chemically defined medium for the production of phase I Bordetella pertussis . J Gen Microbiol 1970, 63:211–220.PubMed 33. Inatsuka CS, Xu Q, Vujkovic-Cvijin I, Wong S, Stibitz S, Miller JF, Cotter PA: Pertactin is required for Bordetella species to resist neutrophil-mediated clearance. Infect Immun 2010, Orotic acid 78:2901–2909.PubMedCrossRef 34. Capiau C, Carr SA, Hemling ME, Pl ainchamp D, Conrath K, Hauser P, Simoen E, Comberbach M, Roelants P, Desmons P, et al.: Purification, characterization, and immunological
evaluation of the 69-kDa outer membrane protein of Bordetella pertussis. Proceedings of the sixth international symposium on pertussis. Bethesda, Md.: Department of Health and Human Services, United States PI3K inhibitor Public Health Service, Food and Drug Administration; 1990:75–85. Competing interests The authors declare that they have no competing interests. Authors’ contributions WB, AL and PP conceived the study. WP, CB, AI and JP designed the experiments. WB wrote the draft of manuscript, JP and WP revised the manuscript. All authors read and approved the final version of the manuscript.”
“Background Klebsiella pneumoniae is a Gram negative member of the Enterobacteriaceae family that commonly causes nosocomial pneumonia, bacteriaemia, urinary tract infections and wound infections [1]. In recent years the treatment of K. pneumoniae infections has become more challenging due to the greater prevalence of multiple antibiotic resistant strains [2, 3].